Supporting Global Approval Of A First-In-Class Gene Therapy For A Rare Genetic Disorder

Bringing a first-in-class gene therapy to global approval requires scientific innovation while also demanding operational precision, regulatory readiness, and the ability to adapt under pressure. In this case study, Veristat supported a biopharmaceutical company developing a transformative therapy for a rare, life-threatening genetic disorder through a multi-year global development program. From IND maintenance and interim analyses to FDA and EMA inspections, as study requirements evolved and regulatory scrutiny intensified, Veristat helped the client maintain momentum, ensure data integrity, and navigate critical submission milestones without disrupting timelines. The collaboration ultimately contributed to regulatory approvals in both the United States and Europe, resulting in the first approved gene therapy for this rare disease and expanding access to patients with limited treatment options.